Illinois Municipal Retirement Fund cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,071 shares of the company's stock after selling 3,647 shares during the quarter. Eli Lilly and Company makes up approximately 0.8% of Illinois Municipal Retirement Fund's holdings, making the stock its 11th largest holding. Illinois Municipal Retirement Fund's holdings in Eli Lilly and Company were worth $52,091,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $43,000. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $48,000. Highline Wealth Partners LLC raised its holdings in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after acquiring an additional 24 shares in the last quarter. Capital A Wealth Management LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $63,000. Finally, Bellwether Advisors LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts recently issued reports on LLY shares. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price on the stock. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Guggenheim reissued a "buy" rating and set a $936.00 target price on shares of Eli Lilly and Company in a report on Friday, June 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $1,011.61.
Check Out Our Latest Stock Report on LLY
Eli Lilly and Company Stock Performance
Shares of Eli Lilly and Company stock traded down $18.94 during trading on Friday, hitting $776.18. 4,109,419 shares of the stock were exchanged, compared to its average volume of 3,683,590. The stock's fifty day moving average is $780.19 and its 200 day moving average is $799.96. The stock has a market cap of $735.61 billion, a PE ratio of 63.16, a P/E/G ratio of 1.13 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.58 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
